Origin Materials, Inc.

Thank you and welcome, everyone, to Origin Materials' second quarter 2023 earnings conference call. Joining the call today from Origin Materials are co-CEO Rich Riley, co-CEO and co-founder John Bissell, and CFO Nate Whaley. Ahead of this call, Origin has issued its second quarter press release and presentation, which we will refer to today. These can be found on the investor relations section of our website at originmaterials.com. Please note on this call, we will be making forward-looking statements based on current expectations and assumptions, which are subject to risks and uncertainties. These statements reflect our views as of today should not be relied upon as representative about views of any subsequent date, and we undertake no obligation to revise or publicly release the results of any revision to these forward-looking statements in light of new information or future events. These statements are subject to a variety of risks and uncertainties that could cause actual results to differ materially from expectations. For further discussion on the material risks and other important factors that could affect our financial results, please refer to our filings with the SEC, including our quarterly report on Form 10-Q filed on August 9, 2023. In addition, during today's call, we will discuss non-GAAP financial measures, which we believe are useful as supplemental measures of origin materials performance. These non-GAAP measures should be considered in addition to and not as a substitute for or in isolation from GAAP results. You will find additional disclosures regarding the non-GAAP financial measures discussed on today's call and our press release issued this afternoon and our filings with the SEC, each of which is posted on our website. The webcast of this call will also be available on the investor relations section of our company website. With that, I'll turn the call over to John.

Thank you, Ashish, and thanks to everyone joining us. Today, we will be referring to the slides that were posted to the investor relations section of our website earlier this afternoon. I will begin with a discussion of Origin 1 startup, provide an update on Origin 2, and discuss product development. Rich will then review our Q2 highlights and provide a commercial and regulatory update. Nate will conclude with a financial overview. Regarding Origin 1 and the continued progress made by our team, I would like to point you to a new video that we posted today in the investor relations section of our website, providing a closer look at plant startup. I will begin on slide 5 with an update for Origin 1. In late June, we announced that OriginOne, the world's first commercial-scale plant to produce origins intermediates, CMF, HTC, and oils and extractives, had initiated startup in line with prior guidance. This is a tremendous milestone in our journey to deharmonize the world's materials. It is also a testament to the strength of our team, which faced considerable COVID-19 and other related supply chain headwinds. OriginOne, located in Sarnia, Ontario, Canada, scales up our core technology platform for converting sustainable wood residues into intermediate chemicals. And we expect the power of our platform intermediates to be transformative for the chemical industry and how the world makes physical goods. OriginOne is first and foremost a strategic asset to qualify applications of our intermediates. Apart from perizymia and biopet, using product from OriginOne, we plan to explore or qualify FDCA, epoxies, resins, surfactants, sustainable carbon black, bioasphalt, and biofuels. We expect to gradually ramp up Origin 1 operations, and we aim to optimally fulfill customer demand while we produce samples and qualify materials. We remain confident that we'll be able to meet our production goals to support our revenue guidance. Origin 1 enables the commercial scale production of CMF, a versatile chemical building block that can be used to make numerous downstream products, including paraxylene, which is a precursor to PET plastic, and SCCA, which can be used in numerous sustainable products and materials such as the next-gen polymer PEF. The commercialization of a molecule like CMF is historic, on the order of the commercialization of the ethylene molecule. After working with CMF for over a decade, we couldn't be more enthusiastic. Turning to slide seven, we say that CMF is a new chemical building block, but what do we mean by that? An important chemical building block has a low cost of production, high versatility across applications, and differentiated performance. What we've seen historically is that when you combine those three qualities, you have a high-impact building block. Throughout history, a relatively small number of key chemicals have unlocked and transformed the chemical industry. The most recent ones, polycarbonate, acrylate, and urethanes, were commercialized in the 1980s. Introducing a new building block chemical is hard and takes time, but it's worth the effort. In 1942, ethylene reached a major milestone, the first production of ethylene through the catalytic cracking of ethane. What followed was decades of process improvements, market penetration, and the rise of ethylene to a $125 billion market. CMF is a similarly powerful molecule due to its low cost of production, high versatility, and differentiated performance. In the case of CMF, the differentiation is the low carbon intensity when it's produced from biomass using the origin process and the performance advantages of some of its applications. Over the next decade, growing CMF will be analogous to growing an oak tree. For the first few years, most of an oak's growth occurs underground as the root system is established. Only then does the tree get taller, stronger, grow branches, and become a mature oak. Similarly, in the chemical building block business, the first phase is to establish a foundation for long-term growth. We are engaged in these foundation building activities every day, and we are excited about and committed to the journey ahead of us. Turning to slide eight, we see CMF's versatility and transformative power. Here, a simplified chemical product manifold describes some of the chemistry that CMF makes possible in an industrial scale. From CMF, we can develop new classes of diols, amines, and diacids, in addition to drop-in molecules like parazymine, which you're familiar with as the precursor to PET plastic. Those chemical families, in turn, can be used to produce a range of surfactants, epoxies, polyurethanes, polyamides, and more. Growing and cultivating the branches of our CMF tree is the job of R&D and the work we do in collaboration with our partners. Turning to slide nine, we're excited to announce the mass production of FTCA, a high-value downstream application for CMF. We'll move forward to Origin 2 rather than Origin 3 as initially planned in April 2021. We're bringing FECA forward for several reasons. First, we've seen stronger FECA commercialization progress than we anticipated two years ago. Second, FECA applications tend to be performance advantaged and thus offer higher margins than Paris Island and PET. Third, we have validated the drop-in deployment of FECA within the PET market, providing a clear pathway to commercialization that is on strategy for us and our customers. Fourth, we are excited for the potential of FTCA in other polyester and nylon applications, and we look forward to providing updates on these as appropriate. In summary, we are seeing broad support and momentum for FTCA commercialization. Indeed, the U.S. Department of Energy has previously shortlisted FTCA as one of the most promising biochemicals of the future. Turning to slide 10, our FTCA go-to-market strategy is to begin with drop-in applications before moving into higher-margin applications requiring additional development work. These drop-in applications are not expected to require meaningful retooling of existing methods of production. We expect to develop FGCA within existing PET markets with the following phase approach. One, commercialize drop-in next-gen hybrid PETF polymers, offering performance advantages compared with traditional PET. Two, commercialize the advanced polymer PEF, which also offers performance advantages compared to traditional PET. Today, we are providing an update for Origin 2, our second commercial plant to be built in Geisman, Louisiana. As just mentioned, we continue to make progress developing products and applications related to the design of Origin 2, including FDCA, PEF, and liquid biofuels derived from our oils and extractives stream. While Origin 2 will focus primarily on FDCA production, and some of our PET customers have already begun expanding their orders to include FDCA, We remain committed to providing paraxylene for our BioPEP customers and plan to bring commercial quantities of paraxylene to the market before 2030. While our current plan is a rational prioritization of Origin's researches towards more profitable, typically performance-enhanced chemical applications at Origin 2, we also see massive demand for our drop-in BioParaxylene. We believe that the best way to meet this demand will be through collaborations with others. We've been in active discussions with multiple strategic partners who are interested in licensing or co-developing low-carbon bio-parasitizing plants using Origin's technology, both in the U.S. and across the globe, and most of which are large, well-capitalized industrial producers of petro-PTA, PET, and other downstream products who recognize the need for more sustainable products. We are also updating our previously disclosed capital budget and construction timeline for Origin 2. As we first indicated in May 2022, we are facing a higher-cost capital project environment than in early 2021 when we announced the initial plan for Origin 2. As such, we are revising the plan's outlook and introducing a phased approach to construction. Adapting in this manner to the high-cost environment helps to reduce project risk as we move forward on the path of profitability. Turning to slide 11, since Origin became publicly traded into 2021, we have witnessed profound market shifts, presenting both opportunities and challenges. Factors influencing our updated plan include significantly higher than anticipated demand for higher margin products, including FPCA, DEF, and liquid biofuels, increased cost of labor, materials, process inputs, and metallurgy due to volatile global material markets requiring engineering rework, inflation and higher interest rates, and higher costs due to COVID-related supply chain constraints and additional value engineering requirements that have extended project timelines. Turning to slide 12, we now expect Origin 2 to be completed in two phases, with Phase 1 estimated to be completed in late 2026 to 2027, and Phase 2 estimated to be completed in 2028, compared with our initial expectation for a mid-2025 completion. During Phase 1, the company expects to achieve profitability from its oils and extractive stream. From this stream, Origin plans to produce a drop-in biofuel with potential applications including marine fuel and heat and power generation. Potential benefits include improved energy density compared with existing renewable alternatives and the sustainability benefits of increased biocontent. Value propositions expected to be in high demand given, among other things, the decarbonization goals set out by the International Maritime Organization, a body of the United Nations. Phase two will expand production to include the mass production of platform chemicals, CMF, and HTC. Phasing the plan is intended to enhance overall efficiency while improving short-term and long-term economics. The capital budget for Phase 1 of Origin 2 is expected to be up to $400 million, while the capital budget for Phase 2 is projected to be up to $1.2 billion. This compares to the original $1.07 billion aggregate capital budget estimate first provided in February 2021. As Nate will discuss in more detail, we are exploring multiple opportunities to finance Origin 2, including a combination of existing cash, previously indicated traditional project financing, federal and state government programs, licensing agreements, and strategic partnerships. We expect capital expenditures of up to $50 million for 2024, with the majority of Origin 2 capital spend to occur following the project's final investment decision, or FID, in 2025. In summary, the Origin 2 project represents a significant scale of our technology, core processing capabilities, This scale-up will be instrumental in enabling Origin to execute on its mission and greatly expands our ability to deliver product and address customer demand. We remain deeply committed to the project, and we will do the work, make the investment, and build the relationships to make Origin 2 a success. With that, I would like to turn it over to Rich, who will review our Q2 highlights and provide a commercial and regulatory update.

Thanks, John. Moving to slide 13, customer demand remains strong, with offtake and capacity reservations now exceeding $10 billion, up from $9.3 billion in February 2023. We are excited to have crossed this significant milestone and to highlight that the majority of the growth in demand was for FTCA, which is where our team has been focused. As mentioned in prior calls, we do not plan to provide updates on this number every quarter, but we'll provide updates as appropriate. We are maintaining 2023 guidance for revenue of $40 million to $60 million, and adjusted EBITDA loss of $50 million to $60 million. We're also pleased that revenue generated by joint development agreements and our supply chain activation program continue to grow in the second quarter in line with guidance. We continue to see strong positive tailwinds for our technology and business model. Origin continues to explore several programs funded by the IRA, or Inflation Reduction Act, including the Department of Energy's Advanced Industrial Facilities Deployment Program, or AIFD. which we expect to hear feedback on by the end of the year, and the Section 48C Advanced Manufacturing Tax Credit. We remain optimistic that these programs could provide meaningful support for the construction of Origins plants. Turning to slide 14, in early August, we were excited to announce a strategic partnership with Sustainia Bioglycols, a joint venture between Braskem, the largest thermoplastic resin producer in the Americas, and a global pioneer in biopolymers, and Sojitz Corporation, a Japanese global trading company with wide-ranging market networks and a strong presence in Asia. Our partnership centers on advanced bio-based materials and is part of the partnership sustaining assigned two multi-year capacity reservation agreements to purchase renewable chemicals from Origin, including bio-based PTA and bio-based FTCA. Turning to slide 15, in late July, we were pleased to announce that Origin and Husky, a pioneering technology provider of injection molding equipment and services to the food and beverage packaging and consumer products industries, had achieved a milestone in the commercialization of PET, incorporating the sustainable chemical FDCA for advanced packaging and other applications. Specifically, Origin successfully polymerized the bio-based sustainable chemical FDCA into the common recyclable plastic PET. Husky then molded the resulting PETF hybrid polymer into preforms that were then blown into bottles. The companies used Husky's injection molding technologies and manufacturing equipment, a commercial manufacturing scale level of processing, demonstrating the ability of PETF, the polymer made with FDCA, to be integrated into existing PET production systems. This innovation demonstrates a pathway for the drop-in market adoption of FDCA to produce superior polymers cost-effectively from biomass using Origin technology. Our PETF polymers offer improved performance compared with traditional PET plastic, with properties like enhanced mechanical performance and superior barrier properties controlled by adjusting manufacturing conditions and the quantity of the FDCA copolymer. Turning to slide 16, in early August, we announced a strategic partnership with Terfane, a global leader in specialty PET polyester films, to produce sustainable, high-performance biopolymer films. As part of the partnership, Terfane signed a multi-year capacity reservation agreement to purchase the advanced biopolymer PEF for use in film applications, including food and beverage packaging in high-value industrial applications. Turning to slide 17, in early August, we announced a strategic partnership with Promen, a leader in natural gas-derived products and one of the world's leading producers of methanol, centered on low-carbon biofuel production, utilizing Origin's technology platform and Promen's worldwide fuels capabilities and expertise. As part of the partnership, Promenade Origin Materials signed an agreement to explore the production and global distribution of low-carbon biofuels. Low-carbon intensity biofuels made from wood waste reflect the future of biofuels as the industry moves aggressively towards decarbonization. Origin's technology platform is uniquely positioned to deliver these renewable fuels using our oils and extractives intermediate stream. We are excited to partner with Promenade. a company that brings significant expertise across engineering, procurement, and construction related to world-scale sustainable technology development. Over the long term, we see the potential for biomass-derived low-carbon-intensity fuels to be used in marine and other transportation fuels, industrial applications, heat and power generation, and more. Turning to slide 18, in early August, we announced a recyclability innovation and new product line with Origins All-PET Bottle Caps Enclosures. In 2021, the global caps and closures market was $65 billion. This market is expected to grow to approximately $100 billion by the end of the decade. Today, caps are typically made from different materials and bottles, presenting challenges for recycling and separating material streams and putting a ceiling on the amount of recycled content that can go into a bottle. The industry has long sought a monomaterial solution for caps and bottles, so we are thrilled to have launched our all PET bottle caps and closures business. Apart from improving post-consumer recycling, our design and manufacturing innovation makes made-with-100% recycled PET possible from cap to bottle. Origins PET caps may be cost-competitively produced with any type of PET, from recycled PET to Origins 100% bio-based carbon-negative virgin PET. Notably, PET performs better than HTPE and PP common cap materials, offering improved oxygen and CO2 barriers. With our PET caps business, we identified a global sustainability challenge and an opportunity to solve it. An all PET bottle and cap enclosure system is an obvious necessary next step in beverage packaging and recycling. We are proud that our team's expertise in PET led to this tremendous advancement for recycling, and we look forward to providing updates on this new business line. I'd like to take a moment to spotlight how our platform is stronger today than when we first became public and provide a look ahead. Turning to slide 19, Over the last two years, our platform evolution can be summarized in one word, performance. When we first listed on the NASDAQ, we called ourselves the world's leading carbon negative materials platform, emphasizing our competitive cost of production and powerful carbon advantage. Since then, we've developed higher margin, higher performance products, such as carbon black for automotive tires and products such as FDCA, PEF, and our hybrid polymer PETF. Reflecting this strong base of innovation, we now have intellectual property across 31 patent families, more than a 50% increase since February 2021. Our performance-advantaged products carry all the benefits of our platform in terms of competitive cost of production and low-carbon footprint, but include additional benefits specific to their applications. Because of our success in these developmental efforts, today we are proud to say high-performance, low-carbon, better materials start with Origin. Turning to slide 20, the Origin platform stands apart from other technologies by offering the best value uplift for biomass. Origin is fundamentally economically advantaged compared to other biomass conversion technologies. This is because of the simplicity of our technology, which is able to chemically convert woody biomass into chemicals, a more direct means of producing intermediate chemicals than alternative processes like paralysis, with almost zero carbon loss during the conversion. Our products can command a premium for their sustainability and performance characteristics across a wide array of applications. The result is that our platform, which has such which acts something like a petrochemical refinery, except utilizing biomass as the key feedstock instead of oil, is able to deliver several times the margin of competing technologies. Turning to slide 21, we expect the gross margins of our intermediate streams to grow stronger with time. Product development, the versatility of our intermediates and economies of scale, will drive long-term value creation. For those who have followed our story, you have already witnessed our platform evolve to take advantage of higher margin opportunities. most notably with the acceleration of FDCA to Origin 2. This is just one example of our strategy of pursuing the highest value, most impactful opportunities for our versatile platform. Turning to slide 22, often we're asked who our competition is. The answer is simple. Capacity is our competition. The chemical industry, our supply chain partners, consumer brands, all of us are working together to achieve the same goal, better materials that help fight climate change. Our ability to grow our business is not limited by competition, it's enhanced by cooperation. The way we win is to bring on additional capacity as quickly, intelligently, and safely as we can. Our strategy is twofold, build and license. While we plan to build, own, and operate Origin 1 and Origin 2, licensing is key to our ability to scale rapidly. Last quarter, we announced our first potential licensing agreement with SCGP. We continue to explore other licensing agreements with many of our customers, and we are well positioned to take advantage of a host of strategic opportunities around the world to increase production strategically in a way that plays to local strengths, whether it's feedstock availability, government incentives, skilled industrial talent, and burning existing facilities or other opportunities. Turning to slide 23, in early June, we were thrilled to announce the appointment of Jim Stefano to the Origin Board of Directors. Jim's proven track record leading manufacturing and technology initiatives for global companies is highly complementary to the skill set of our board, and will prove invaluable as we ramp up Origin 1 operations throughout the year and begin commercial production. Jim brings to Origin over 30 years of experience in the manufacturing, operations, and engineering, including his current role as CEO of Integrated Project Services, an engineering and construction services provider to the life sciences sector. With that, I will turn it over to Nate to discuss some of the financial details.

Thanks, Rich. I'll begin with a commentary on our second quarter results, then provide our financing expectations for Origin 2, And finished with an update on our 2023 outlook. Speaking to slide 24, we reported quarterly revenue for the second quarter of $6.9 million associated with JDAs and Origins Supply Chain Activation Program compared to no revenue in the prior year period. Second quarter operating expenses were $14.4 million compared to $8.7 million during the same period in the prior year. Net loss was $6.3 million for the second quarter compared to net income of $46.9 million in the same period in the prior year. Adjusted EBITDA loss was $11.7 million for the second quarter compared to a loss of $6.9 million in the same period in the prior year. Turning to our balance sheet, Origin ended the second quarter with $217.7 million in cash, cash equivalents, and marketable securities. A meaningful portion of Q2 cash expenditures were related to the completion of Origin 1 and are therefore non-referring. Regarding the financing of Origin 2, in early January, we announced that the Louisiana State Bond Commission unanimously passed a resolution granting its final approval of the issuance of up to $1.5 billion of tax-exempt bonds to support the construction and commissioning of the plant. This amount is inclusive of and builds on the strong foundation of the previously announced expected $400 million in private activity bond volume cap allocation. Bank of America has been engaged by Origin to underwrite the bonds and market them to investors. We continue to believe that debt financing of Origin 2 could be achieved using entirely tax-exempt bonds. Origin continues to work with leading financial institutions on other forms of traditional private financing and federal loan programs, including through the United States Department of Agriculture and Department of Energy, to pursue other local, state, and federal incentive programs to optimize the financing of Origin 2. These include certain 2021 Infrastructure Investment and Jobs Act and 2022 Inflation Reduction Act provisions including the Department of Energy's Advanced Industrial Facilities Deployment Program, or AIFD, and the Section 48C Advanced Manufacturing Tax Credit. Finally, given Origin's ongoing global technology licensing effort and an active government affairs team, we anticipate strategic partnerships as well as state and federal incentive programs to play a meaningful role in the financing of Origin 2. I will wrap up with our 2023 outlook. We are maintaining our guidance for revenue of $40 to $60 million and an adjusted EBITDA loss of $50 to $60 million. And with that, I will turn it back to Rich for closing remarks.

Thank you, Nate. In closing, I would like to thank our customers, our team, and our partners for their contributions to our company's success and our shareholders for their support. I'm proud of our team's continued execution as we draw closer to commercial production and take the next step in the world's once-in-a-planet transition to sustainable materials. With that, I will ask the operator to open the line for questions.

Thank you. We will now begin the question and answer session. To join the question queue, you may press star, then 1 on your telephone keypad. You will hear a tone acknowledging your request. If you are using a speakerphone, please pick up your handset before pressing any keys. To withdraw your question, please press star, then 2. The first question comes from Steve Bryan with Bank of America. Please go ahead.

Yes thank you. One a couple of questions here on Origin 2. What is the is any of the delay and the cost increase because of shifting the focus away from paraxylene over to FDCA. I kind of suspect not but wondered if that was part of it and maybe more importantly When you first rolled out your financials from Origin 2, you were targeting a million tons of biomass feedstock into that plant. Is that still the design? But more importantly, you were targeting 16 cents a pound of margin from this PET pathway. As you move towards more of a FDCA pathway, what would you suggest is a more reasonable margin that that plant you think is going to be able to produce?

Hey, Steve. Thanks for the questions. Good questions. So first, I'll go through each one in order. So first, you asked, you know, is FDCA and shifting towards that kind of product base part of the capital increase and schedule shift? And the answer actually is, in part, yes. It's not the only thing, but it's meaningful. So looking at these other products, one, takes more time, right? So we obviously didn't expect to be producing those kinds of products off of OM2 when we originally provided our estimates on schedule and cost. And so there are changes that get made. I'd say, you know, generally speaking, if you're looking at FTCA, that has more of a schedule impact than it does an overall cost impact. And then for things like Carbon Black and other higher value HTC products, that has both a schedule and a cost impact. So those are a part of it, although, again, they're not the only thing. They're not solely responsible for that. From a scale perspective, you know, one of the things that's somewhat unusual for Origin specifically as a chemical company is that we tend to be more capital constrained than the typical chemical company that's going after the kinds of plants and projects, frankly, technologies that we are. And so, consequently, we have to adapt to increased cost environments by also reducing the scope of the plant, not just by raising additional capital, right? We need to be disciplined with the way that we approach these kinds of projects. And so consequently, in a higher cost environment where we're going in general, right, which includes some of the things that we enumerated, but things like higher materials prices, obviously higher labor costs, energy, all sorts of things like that. As a consequence of those, we need to adjust by scoping down the scale of the plant. And so, we expect that we're going to have a smaller scale plant than the million tons of biomass fed originally. And we provide a summary of that on one of the appendix slides in our earnings presentation. But generally speaking, we're expecting by the time we're done with this plant to be at about 500 KTA of feedstock rather than a million. Sorry, and then margin. So, for margin, we haven't given an explicit margin as a result of all of those things. What you can see is if you, on that same slide that I just referenced, which is in the appendix portion of the presentation, what you can see is 500 KTA of feedstock, and we're expecting just under $300 million per year of EBITDA on that.

Thank you.

The next question comes from Frank Mitch with Fermium Research. Please go ahead.

Good afternoon. Good afternoon, folks. Yeah, it seems like a pretty big pivot on Origin 2, particularly when you're going after biofuels. Can you talk about the risks associated with that, given the fact that you have all these capacity reservations on paraxylene You know, that was kind of the first thing in hand. And also in terms of the capacity reservations and so forth, you know, now that you're pivoting and delaying, you know, pretty meaningfully, you know, what are the chances that some of those capacity reservations go away? But, yeah, if you could talk about the, you know, the timing delay, the pivot, and why is the FID in 25, not in 24? Sure.

Yep. So thanks, Frank. Appreciate the questions. So first one is, you know, on market demand in general, so for both the Biofuels product and also for FECA and some of our HTC-related products, I think we see very, very strong demand for each of those three product categories. I think, you know, it's worth saying that that was a very significant contributor to our view of of the new product slate and the new scope for Origin 2, and absolutely not to be underestimated. That said, of course, a huge proportion of our capacity reservations and opt-in agreements are, as you said, for paraxylene. We have seen so far customers are very committed to the long-term of paraxylene with us. And we, of course, are no less excited about paraxylene than we have ever been. And in fact, as we mentioned, I think during the earnings script, we really see a very attractive pathway forward for paraxylene that takes advantage of working with strategic partners of various sorts who have lower costs of capital for these sorts of things in general as compared to origin right now. So we're excited about paraxylene. We remain excited about it. Our customers remain excited about paraxylene. And frankly, a huge part of the look towards products such as FDCA and the Spinal Seals product are the result of demand, very strong demand from customers for this product.

Gotcha. And, you know, as you indicated, you know, capital constraints were also a part of this decision. Just curious, let's assume, let's hypothetically say that nine months from now, we've had really smooth operations at origin one. And so let's say that would attract a strategic or another party that would be willing to make a very large capital commitment, capital injection. Would that accelerate the timeline? How do you think about taking on a strategic financial partner? as I said, sometime in 2024?

Yeah, I think it's a really interesting question. I think, you know, we tend not to think in hypotheticals around these sorts of things, but I will say, you know, just generally as a company that is, you know, small relative to some of the chemical majors out there, there are limits to the number of things that we can do in parallel. And so anytime that we have access to additional resources, that can have an impact on schedule.

Have an impact on schedule.

All right. Hey, thanks so much.

The next question comes from John Roberts with Credit Suisse. Please go ahead.

Thank you for slide 27 with the Origin 2 Economic Summary. If I just divide EBITDA by CapEx, the return on Phase 1 is 20% and the return on Phase 2 drops a little bit to 17.5%. Why is Phase 2 not higher than Phase 1?

Yeah, it's an interesting question. I think our view there is that, one, because it's a little bit further out, we have, frankly, a different level of specificity around some of the Phase II elements. And so that just inherently we're going to give that a little bit more of a discount from our view. I think the other is there are – significant parts of phase one and phase two that you could argue are sort of arbitrary as to whether we count them as part of phase one or phase two. We didn't try to load balance too carefully between the two, but a lot of benefits are realized with phase two beyond just the fact that we're getting access to larger markets for those products, that we're getting access to all kinds of sort of mission-driven sort of objectives with phase two as well. So we do see them as relatively well and synergistically linked. but to your point, phase one standalone is an attractive project all on its own.

And then do you think you'll have a new CFO in place by September 1st or what's the backup plan there?

Oh, go ahead and Rick. Sorry.

I was going to say, we've, you know, we were, we're active. We've retained a large leading executive search firm. We've got an exciting pipeline of candidates. And so, um, We're very much in the process. Don't yet have a start date planned, but we've got Nate with us through September 1st, and he's got an advisory role through the end of the year, so we're confident that we will have a smooth transition.

Thank you.

The next question comes from Eric Stein with Craig Hillen. Please go ahead.

Hi, everyone. Maybe I'll just start with the order book. I know, you know, 10 billion plus, as you just said, I mean, most of that's paraxylene and, and I know those customers are committed to the longterm, but I mean that this means with this change of the timeline that they're waiting quite a bit. I mean, is there, are there any mechanisms within that, that if it's a customer that, you know, would have a need for FDCA? I mean, what's the, How does that work? Or, I mean, is there the potential that you hand off some of this order book to a potential licensee? Or, I mean, just trying to think about that dynamic from the customer's point of view.

Sure. Well, Eric, we were excited to cross the $10 billion milestone, and a lot of the recent growth was from FDCA, which has been a large focus of ours in recent quarters. And many of our paraxylene customers do also have an interest and, in many cases, a capacity reservation with us for FDCA. So there certainly are synergies in those two materials for many of our customers. But we do have a large order book for paraxylene and PET, and we are very committed to delivering against that order book and are optimistic that we'll be able to deliver those materials in the timeframe that those customers want. and largely in partnership with other companies. And if you think about, you know, we talked about SCGP recently. We've talked about our Indorama relationship. There are, you know, multiple partners that we're working with that have the potential to help us deliver, you know, bio-parazylene at large scale in a relevant timeline for those customers. And those customers very much want those materials. There really aren't any other ways of getting them. And so we are very optimistic that they'll continue to work with us to deliver those materials.

Got it. And then, you know, just as we think about the change in the timeline, you know, I can appreciate higher, obviously higher interest rates, but, you know, I mean, that's a new dynamic since, you know, this all got started and you first gave that number for Origin 2 back in 2021, but it's not new here over the last, number of quarters. So, I'm just trying to kind of think about, you know, how much of this can be ascribed to that, a higher rate environment, versus, as you said, it's FDCA. You just need, you know, more time needed on the development side.

Yeah. So, really, I think the first thing that's worth thinking about is, and keeping in mind, is how long it takes to turn a new engineering investment And so, you know, as we have made adjustments and thought about sort of how to put both the opportunities that have been presented and the challenges that have arisen into a sort of bucket and then figure out, well, what's the best way to navigate through those sorts of things? You know, generally speaking, it can be very difficult to understand what the impact of those is going to be on something like a final cost or a revenue number or even a schedule, frankly, until you turn that through tens of thousands of hours of engineering time to convert that into a new scenario. And in our case, we were actually running multiple scenarios. You put them in, you put them into the black box, and you get them out for a period of time. And so our view was, generally speaking, we need to process all of this information. And it wasn't really until all that recently that it made sense to take a different scenario approach to this. I think it's also worth mentioning that it's not just rates, right? So rates are one part of it, and they are a meaningful part. But there are other things as well that have an impact. Again, I mentioned sort of labor rates, materials costs, even energy volatility and volatility around some of these things can have a pretty significant impact in the way that you have to structure the risk management around plants like this.

Okay, I'll take the rest offline. Thanks.

The next question comes from Pavel Molchanov with Raymond James. Please go ahead.

Thanks for taking the question. And as one of the earlier speakers said, appreciate the clarity on the origin to economics. Yes, my question about that is, given that you'll be selling into the biofuel market where policy incentives, you know, RINs and LCFS, et cetera, play such a pivotal role. What are your assumptions about, you know, what kind of federal tax credit or, you know, carbon credits or anything along those lines? What's embedded in those EBITDA metrics?

Yeah, so we haven't put a significant amount of credit value into our product values there. A lot of it has been driven by the customer application value and then specific offtake conversations and negotiations with specific customers. So generally speaking now, of course, they are very tightly tied to the regulatory and policy measures around these sorts of things. But we've tried to be very customer centric in the way that we're approaching the value there. not really looking to the regulatory aspects nearly as much at this point.

Okay. So you highlighted the marine market as kind of one of the prime verticals where you hope to be selling. I guess, why marine versus, let's say, sustainable aviation fuel?

Great question. It has to do with the technical components of the fuel that we're producing. And so that fuel in particular, while it is a somewhat, let's say, flexible kind of fuel, it has some real particular benefits in the marine market. And that's part of the reason why Proman, who we announced today, is a very interesting and relevant partner for us.

Got it. Thanks very much.

That concludes today's live Q&A segment. I will now turn it over to Ashish Gupta, Investor Relations, to conduct the next segment of our investor Q&A. Please go ahead.

Thank you, Operator. As has become custom on our earnings calls, we invite all investors to submit questions for our second quarter call as part of our Ask Origin campaign. In the interest of time, we'll be taking the most commonly asked questions. Our first question is for John. When Origin is producing its first CMF, when is Origin producing its first CMF made from waste? How long does it take to produce a batch of CMF from feedstock?

Yep. So, thanks for the question, Ashish, and whoever submitted to ask Origin. So we expect to produce the first batches of CMF from wood waste from origin one. We expect that to be a matter of really weeks for first CMF production and not too much longer than that for first CMF from wood waste specifically. So we're quite close now and we're pretty excited about it. Generally speaking, you know, we often get the question of, you know, what's the characteristic reaction or process time associated with converting feedstock into our intermediate products? Often that can be a useful way for people to think about differentiating, you know, a very slow and capital-intensive process from one that's quicker and generally less capital-intensive. And our characteristic sort of process times are on the order of sort of minutes, maybe up to as much as an hour if you include all of the residence times and the various pieces of process equipment beyond the reactor. So it's pretty quick. You put a chip in one side and you get a chip's worth of CMF out the other side in about half an hour to an hour, something like that.

Great. Thanks for that, John. Just turning to carbon black, is Origin Materials partnering or running any research for expanded commercial uses of carbon black at this time?

Yeah, we're really excited about Carbon Black. So we've mentioned it quite a few times. We've mentioned it all the way back to since 2021. But when we talked about it then, we thought of it as a sort of far future, sort of post-OM2, maybe a little bit in OM3, and sort of progressively becoming a larger proportion of the product mix. We, as I mentioned earlier, alongside FDCA, we've seen Carbon Black be a really much more meaningful part of the demand now. And what's really interesting about our carbon black in particular is that it starts with a very different surface chemistry than traditional carbon black made from fossil sources like natural gas or fuel oil, something like that. And that gives us an interesting cost and performance advantage in a lot of the areas of carbon black that are considered specialty carbon black. So in many ways, our material starts as a very high value specialty type material compared to the existing market. And then as we do additional processing, somewhat ironically, we actually bring it down closer to the performance of the commodity carbon blacks. Whereas if you look at the traditional processes for making carbon black, it's the inverse, right? So they start with something very close to a commodity carbon black, and then they do a bunch of work and put a bunch of money in in order to get them to the specialty end. So that sort of unusual position has made us a lot more bullish on carbon black in the near term and at high value. So we're really excited about it. We do work both with other uh experts and and producers in the carbon black industry and with end customers so we do a lot of application development work with customers in general across all of our platform molecules but that's still true with htc and by the way that kind of application development work is what leads to things like the caps business that we described earlier so it's it's that working very closely with customers to solve very specific products and technical problems that we think really gives our platform an edge in getting into all of these different markets and getting the value that our platform intermediates really deserve.

Thanks so much, Sean.

With that, we'll turn to some questions for Rich. Speaking of caps and closures, Rich, why is Origin pursuing the all PET bottle cap opportunity when you already have $10 billion in customer demand?

Yeah, it's a good question. And, you know, we really got into this business through serendipity that comes from being very close to our very large customers and their R&D teams and then having world-class polymer scientists on our side. And what ended up happening was we figured out how to solve a real problem in this form of packaging and that we could solve it with PET. So today's caps are made from HDPE or polypropylene which are harder to recycle and cause, you know, reduce the amount of recycled content you can put into a bottle and cause issues in the recycling chain. We figured out how to do it and secured the IP to do it with PET and really any form of PET, recycled PET, our PET. And so we're excited that we have this very big and growing market opportunity. A product that is performance enhancing and solves a major sustainability challenge. that we can do it cost competitively with the legacy products. And this business is unconstrained by our construction schedule. So we can be in market very, very rapidly. So we're excited about this very complimentary and very on mission business line.

That is very exciting. If we could move to JDAs, can you get into more detail on the JDAs and give us more color on the goals and parameters of these types of arrangements?

Yeah, so JDA stands for Joint Development Agreement. And the way to think about it is that we are an upstream manufacturer of really three principal intermediates, CMF, HTC, and oils and extractives. And those intermediates go on to make a very wide range of applications, some of which we put into the earnings presentation today. And so what makes sense for us to do is partner with companies that have very deep expertise in getting from our intermediate all the way to a final application. And so an example is Carbon Black, which was talked about earlier. So we are talking to multiple Carbon Black companies that have incredible expertise in Carbon Black R&D. And so we view them all as potential partners, not competitors. And it makes a lot of sense for us to leverage their technical expertise with our expertise at the intermediate level and get to higher value applications, get to market faster, and prevent us from having to have deep technical expertise that goes all the way to each application when we can find partners that have decades of experience in many situations. Another example is the announced partnership with SCGP, and that's a joint development agreement where we're working with a leading company that wants to explore using a specific feedstock, in this case eucalyptus, to go through our process to come out with bioparazylene as the primary target on the other side. And so that's a great chance to partner with someone who has a proprietary feedstock access, a lot of expertise in the space. And so that's another example of an exciting JDA for us.

Great. Thanks so much, Rich, and John, of course, as well. That'll conclude today's Q&A portion of the call. I'll now turn it back to Rich for closing remarks.

Thanks, Ashish, and thank you all for joining us today. This concludes the call.

This concludes today's conference call. You may disconnect your lines. Thank you for participating, and have a pleasant day.